Collaboration Advances Preeclampsia Research in Low- and Middle-Income Countries
Sao Paulo, Brazil – October 24, 2016 – Last night at the opening ceremonies of the World Congress of the International Society for the Study of Hypertension in Pregnancy (ISSHP) in Brazil, the Preeclampsia Foundation, along with its partners ISSHP and the PRE-EMPT/Global Pregnancy Collaboration (CoLab), announced the recipient of their EMPOWER Award for preeclampsia-related research.
Dr. Sarah Manyame, a physician-researcher with the Department of Obstetrics and Gynaecology at the University of Zimbabwe Parirenvatwa Group of Hospitals, was awarded $60,000 USD for her two-year project “Urine Biomarkers for Preeclampsia in High Risk Women.” Dr. James Roberts with the Magee-Womens Research Institute in Pittsburgh, Pennsylvania, will serve as Dr. Manyame’s mentor.
EMPOWER (EMpowering Progress in Obstetric and Women’s hEalth Research) was established to create partnerships between mentors and medical researchers within low- and middle-income countries to improve clinical and health services research into hypertensive disorders of pregnancy. Ninety-nine percent of maternal deaths from preeclampsia occur in low-resource settings like Zimbabwe, where 35 percent of maternal mortality is due to preeclampsia and eclampsia.
“This is the second award granted to a preeclampsia researcher from a low- to middle-income country through EMPOWER,” said Eleni Tsigas, Executive Director of the Preeclampsia Foundation. “We’re pleased to continue this program, welcoming ISSHP, PRE-EMPT/CoLab, and supporting organization New Zealand Action on Pre-eclampsia.”
With the resource constraints facing the country, Dr. Manyame said, “Zimbabwe needs a readily available, simple non-invasive test for the prediction of preeclampsia and the severity of the outcomes. Thus, this study will evaluate the preeclampsia predictive value of the Congo red Dot test, protein/creatinine ratio, calcium/creatinine ratio, PlGF/soluble Flt-1 ratio, in women at high risk and at varying stages of the disease.”
The immediate objective will be the completion of the project designed by Dr. Manyame and, when appropriate, the dissemination of the results of the study to change practice and improve care. A fundamental goal of the program is to build independent capacity for research and effective local implementation of research findings. Other objectives include developing an integrated hypertension research team, advancing the knowledge base, and supporting research operations.
Preeclampsia, the most dangerous form of pregnancy hypertension, is estimated to contribute to at least 120 maternal and 1,300 fetal or newborn deaths every day throughout the world, primarily in regions such as the Indian subcontinent, Africa, and Latin America. Most of these cases are considered preventable.
Your story is needed to improve outcomes for moms like you. Add your voice to critical preeclampsia research to ensure that every story is heard.
Frequently asked questions about the Preeclampsia Registry, a patient-driven registry and biobank.
The Preeclampsia Foundation offers research funding, study recruitment, and other patient engagement services to researchers.
We provide research grant funding to advance progress towards detection, prevention, or treatment of preeclampsia, HELLP syndrome, and other hypertensive disorders of pregnancy.
Preeclampsia is a major cause of maternal and fetal morbidity and mortality. Prompt and accurate diagnosis is necessary to prevent adverse outcomes. A study was completed to determine the accura...
Predicting preeclampsia has proven to be a challenge. Researchers have documented many differences in early pregnancy between those who eventually develop preeclampsia and those who do not. These incl...
The U.S. Preventive Services Task Force (USPSTF) and American College of Obstetricians and Gynecologists (ACOG) guidelines changed in 2021 to help prevent preeclampsia. Low-dose aspirin has been shown...
Hypertensive disorders of pregnancy (HDP), including preeclampsia, affect 1 in 6 pregnancies. HDP is a general term for a range of mild to severe outcomes. Until now there has not been a reliabl...
Although there is no definitive treatment for preeclampsia, early screening and detection can allow patients to ensure proper management throughout the remainder of the pregnancy. Currently, preeclam...